Last reviewed: June 30, 2026

Last updated: June 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Obesity affects roughly 20% of U.S. adolescents, yet most weight-loss medications remain unavailable to teens under strict FDA guidelines. Ozempic (semaglutide) is not approved for teenagers, but emerging evidence and compounded alternatives are changing the landscape of adolescent weight management for qualified candidates.

FDA Approval Limits for GLP-1 Medications in Adolescents

Ozempic carries an FDA indication only for adults with type 2 diabetes and cardiovascular risk factors. Wegovy, the weight-loss formulation of semaglutide, is approved only for individuals 12 years and older, but requires a BMI at or above the 95th percentile for age and sex or a BMI of at least 35 kg/m². Tirzepatide (Mounjaro, Zepbound) does not yet have pediatric approval in the United States.

The lack of broad adolescent approval reflects the historically limited clinical trial data in younger populations, not necessarily a safety concern. Most GLP-1 trials enrolled primarily adults, leaving regulatory agencies cautious about extrapolating findings to minors without dedicated pediatric studies. However, smaller trials and real-world data are beginning to establish safety profiles in adolescents who qualify medically.

Medical Eligibility: When Teenagers May Qualify for GLP-1 Therapy

Adolescents with type 2 diabetes may be eligible for semaglutide under its diabetes indication, provided they meet clinical criteria and have provider approval. Those with severe obesity (BMI ≥ 35 kg/m² or ≥95th percentile) and at least one weight-related comorbidity—such as hypertension, sleep apnea, or metabolic syndrome—may qualify for Wegovy if they are 12 or older. Every case requires careful evaluation by a healthcare provider familiar with pediatric obesity medicine.

Beyond FDA-approved pathways, some qualified providers prescribe compounded semaglutide to adolescents with severe obesity and failed lifestyle interventions, supported by emerging clinical evidence. PlexusDx partners with licensed 503A compounding pharmacies to deliver personalized, quality-assured medications to qualified patients across all 50 states, without insurance requirements.

How Compounded Semaglutide Differs from Branded Ozempic

Compounded semaglutide contains the same active pharmaceutical ingredient as Ozempic and Wegovy but is prepared by licensed 503A compounding pharmacies to meet individual patient needs. Compounded options allow for dose flexibility and cost reduction—PlexusDx compounded semaglutide starts at $149 per month—making treatment accessible without reliance on insurance coverage or membership fees.

All PlexusDx medications are HSA/FSA eligible and manufactured under strict pharmacy oversight. The key distinction is that compounded medications are not FDA-approved products but are legally prescribed by qualified healthcare providers when branded alternatives are unavailable, unaffordable, or unsuitable for individual circumstances. Adolescent patients and guardians should discuss the benefits and considerations of compounded therapy directly with their PlexusDx provider.

Genetic Insights: Personalizing Teen Weight Loss with Precision Peptide Testing

Not all adolescents respond equally to semaglutide or tirzepatide. Genetic variations in the GLP1R, GIPR, FTO, and MC4R genes influence appetite regulation, satiety signaling, and metabolic rate. The PlexusDx Precision Peptide Genetic Test identifies these and 46 additional peptide-pathway variants, allowing providers to predict individual response patterns and optimize medication selection from the start.

For qualifying teens, genetic testing costs $99 after the first month of treatment and maps 14 biological pathways across 150+ insights. This personalized approach helps avoid months of trial-and-error dosing and increases the likelihood of sustained weight loss and improved metabolic health. Adolescents with a strong family history of obesity or poor response to previous interventions benefit most from this precision-medicine strategy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can my 17-year-old daughter take Ozempic for weight loss?

Ozempic is not approved for weight loss in any age group; it is indicated only for type 2 diabetes in adults. Wegovy (semaglutide for weight loss) is approved for ages 12 and up, but only if your daughter meets strict BMI and comorbidity criteria. A PlexusDx provider can evaluate her medical history and determine eligibility for compounded or branded GLP-1 therapy.

What clinical evidence supports GLP-1 use in teenagers?

The STEP TEENS trial (2023) demonstrated that semaglutide reduced body weight by approximately 16% in adolescents over 68 weeks, compared to 2% with placebo. Real-world data from compounding pharmacies and pediatric obesity centers continues to support safety and efficacy. However, long-term adolescent outcomes remain an active area of research.

How much does compounded semaglutide cost through PlexusDx?

PlexusDx compounded semaglutide injection starts at $149 per month across all commitment tiers—your dose may increase, but your monthly price will not. No insurance is required, and HSA/FSA accounts are accepted. Pricing is flat regardless of dose level, making treatment predictable and affordable.

Are there any safety concerns with GLP-1 medications in teens?

The most common side effects are gastrointestinal—nausea, vomiting, diarrhea—which typically decrease over time as the body adapts. Rare concerns include pancreatitis and thyroid effects, monitored through regular provider check-ins. Adolescents require closer monitoring than adults and should only use GLP-1 therapy under direct medical supervision with a qualified healthcare provider.

Could genetic testing help predict how my teen will respond to semaglutide?

Yes. The PlexusDx Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, MC4R, and 45 other peptide-pathway genes that influence appetite, satiety, and metabolic response. At $99 after the first month of treatment, this test helps providers predict individual response and personalize medication selection and dosing from the outset.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves